Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT

Antiviral Therapy

Volumn 19, Issue 3, 2014, Pages 277-285

  Kawakami, Yoshiiku ^a   Suzuki, Fumitaka ^b   Karino, Yoshiyasu ^c   Toyota, Joji ^c   Kumada, Hiromitsu ^b   Chayama, Kazuaki ^a,d  

^a HIROSHIMA UNIVERSITY   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c Sapporo Kosei General Hospital   (Japan)

^d RIKEN Center for Integrative Medical Sciences   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; URIC ACID; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; JAPANESE (PEOPLE); LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTE COUNT; URIC ACID BLOOD LEVEL; VIRUS LOAD; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84902689630     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2706     Document Type: Article

References (22)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
2. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538.
3. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36 Suppl 1:S21-S29.
4. Seeff LB, Hoofnagle JH. National Institutes of Health consensus development conference: management of hepatitis C: 2002. Clin Liver Dis 2003; 7:261-287.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al. TVR for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
6. Zeuzem S, Andreone P, Pol S, et al. TVR for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
7. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided TVR combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
8. Kumada H, Toyota J, Okanoue T, et al. TVR with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56:78-84.
9. Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of TVR, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012; 19:e134-e142.
10. Ohnishi Y, Tanaka T, Ozaki K, et al. A high-throughput SNP typing system for genomewide association studies. J Hum Genet 2001; 46:471-477.
11. Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylargininedeiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34:395-402.
12. Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphism on decreases of hemoglobin during treatment with pegylated IFN, ribavirin and TVR. Hepatology 2011; 53:415-421.
13. Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48:372-380.
14. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46:403-410.
15. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131:997-1002.
16. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
17. Suzuki F, Suzuki Y, Sezaki H, et al. Exploratory study on TVR given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res 2013; 43:691-701.
18. Marcellin P, Forns X, Goeser T, et al. TVR is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or 2b to patients with chronic hepatitis C. Gastroenterology 2011; 140:459-468.
19. Buti M, Agarwa K, Horsmans Y, et al. OPTIMIZE Trial: non-inferiority of twice daily telaprevir versus administration every 8 hours in treatment-naive, genotype 1 HCV-infected patients. 63rd American Association for the Study of Liver Diseases. 9-13 November 2012, Boston, MA, USA. Abstract LB-8.
20. Chayama K, Hayes CN, Abe H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and TVR triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204:84-93.
21. Akuta N, Suzuki F, Miharu M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to TVR with peginterferon and ribavirin. Hepatology 2010; 52:421-429.
22. Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45:164-171.